Compare uniQure N.V. Ordinary Shares (QURE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs State Street SPDR S&P Biotech ETF — how do they compare? uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B), while State Street SPDR S&P Biotech ETF trades at $147.16 (market cap $10.05B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 6.9× uniQure N.V. Ordinary Shares's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| QURE | XBI | |
|---|---|---|
Market Cap | $1.45B | $10.05B |
Volume | 3,323,243 | 10,367,649 |
Sector | Health | Broad Market / Factor |
52-Week High | $70.59 | $169.55 |
52-Week Low | $9.03 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $707.46M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $146.8, down 3.04% today amid a bearish technical signal. The ETF's modified equal-weight structure provides exposure to over 150 biotech names, benefiting from M&A activity and positive clinical catalysts. Recent news highlights a 76% prior-year rally and optimism around cancer vaccine breakthroughs from Merck and Moderna. However, the ETF carries higher volatility and expense ratios compared to broader healthcare funds.
Outlook remains mixed with technical indicators bearish but fundamental catalysts present. Investment opportunity lies in targeted biotech exposure and sector innovation, though risks include high volatility, regulatory uncertainty, and reliance on clinical trial successes. Analyst consensus is neutral with 100% hold rating, suggesting cautious optimism amid recent price declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
